On Thursday, Following Stocks were among the “Top 100 Gainers” of U.S. Stock Market: LyondellBasell Industries N.V. (NYSE:LYB), Willbros Group Inc. (NYSE:WG), Synergy Pharmaceuticals, Inc. (NASDAQ:SGYP), Gevo, Inc. (NASDAQ:GEVO)
LyondellBasell Industries N.V. (NYSE:LYB), with shares gained 2.88%, closed at $87.86.
Willbros Group Inc. (NYSE:WG), with shares jumped 7.89%, settled at $3.42.
Synergy Pharmaceuticals, Inc. (NASDAQ:SGYP), with shares climbed 7.72%, and closed at $4.11.
Gevo, Inc. (NASDAQ:GEVO), surged 8.03%, and closed at $0.269.
Latest NEWS regarding these Stocks are depicted underneath:
LyondellBasell Industries N.V. (NYSE:LYB)
LyondellBasell Industries N.V. (LYB), declared plans to expand Tri-ethylene Glycol (TEG) production capacity at the corporation’s existing ethylene oxide and ethylene glycol plant in Pasadena, Texas.
The additional capacity of 50 million pounds per year would more than double the corporation’s current production capacity. Engineering is already underway on the new unit, which is anticipated to be operational in late 2016. It is predictable to be one of the world’s largest on-purpose TEG production units, meaning the TEG is produced by design and not as a by-product of another manufacturing process.
TEG is a colorless, odorless glycol that is used to dehydrate natural gas and as an additive in hydraulic and brake fluids, among other uses. The corporation’s Bayport Underwood plant in Pasadena produces ethylene oxide, ethylene glycol, glycol ethers and other products. Glycol ethers are used to manufacture brake fluid, dyes, paint, solvents, commercial cleaners and waxes, detergents and cosmetic bases. Ethylene glycols are used as intermediate chemicals to produce polyester (PET) fibers, films and bottles.
LyondellBasell Industries N.V. operates as a manufacturer of chemicals and polymers, refiner of crude oil, producer of gasoline blending components, and developer and licensor of technologies for production of polymers.
Willbros Group Inc. (NYSE:WG)
Formerly on March 19, Willbros Group Inc. (WG), declared that it has closed the transaction for the sale of all outstanding stock of its UtilX partner to Novinium, Inc., Auburn, Washington. Willbros will apply net proceeds from the sale to debt reduction, predictable to be in the range of $35 to $40 million, after customary closing costs and adjustments.
“This attainment will improve industry competition by providing a strong alternative to the capital intensive process of replacing underground utility power cables in order to maintain the world’s aging electrical distribution infrastructure,” said the CEO of Novinium, Glen Bertini. “Failing cable is a top contributor to both rising utility costs and customer power outages, and together UtilX and Novinium can offer the safest, most cost effective solutions for cable rehabilitation, extending the effective cable lifespan by as much as 40 years.”
Willbros Group, Inc. operates as an energy infrastructure contractor serving the oil, gas, refinery, petrochemical, and power industries worldwide. The corporation provides engineering, procurement, and construction (EPC), turnarounds, maintenance, facilities development, and operations services to industry and government entities. Its Oil & Gas segment offers construction, project administration, maintenance, and lifecycle extension services to the upstream, midstream, and downstream markets.
Synergy Pharmaceuticals, Inc. (NASDAQ:SGYP)
Formerly on March 16, Synergy Pharmaceuticals, Inc. (SGYP), stated its financial results and business update for the fourth quarter and the year ended December 31, 2014.
On the other hand, the company is talking to advisers about options counting the sale of the corporation, Bloomberg stated, citing sources.
The gastrointestinal drug developer, which had a market value of about $370 million on Wednesday, is exploring a sale after competitor Salix Pharmaceuticals Ltd agreed to be bought earlier in March, the report said.
Synergy spokeswoman Gem Gokmen said the corporation does not comment on rumors.
Synergy’s lead experimental drug, plecanatide, is undergoing development to treat irritable bowel syndrome and chronic idiopathic constipation (CIC).
Synergy Pharmaceuticals Inc., a biopharmaceutical corporation, focuses on the development of drugs to treat gastrointestinal (GI) disorders and diseases. Its lead product candidate is plecanatide, a guanylyl cyclase C receptor agonist that is in Phase III clinical trials to treat chronic idiopathic constipation GI disorders; and for the treatment of constipation-predominant irritable bowel syndrome GI disorders.
Gevo, Inc. (NASDAQ:GEVO)
Gevo, Inc. (GEVO), declared its financial results for the three months ended December 31, 2014 and offered an update on recent corporate highlights.
In the fourth quarter of 2014, Gevo continued to progress the commercial operation of isobutanol at Luverne under the Side-by-Side mode of production (SBS), meeting its stated milestone in December 2014 of producing greater than fifty thousand gallons of isobutanol in one month. This achievement was a result of the introduction of Gevo’s second-generation yeast biocatalyst at the plant, in addition to noteworthy process improvements learned by Gevo since switching the plant to SBS production earlier in 2014.
The data generated at the Luverne plant and in the labs in Denver continues to support ultimate, optimized isobutanol production costs that would support EBITDA margins for isobutanol of $0.50-$1.00 per gallon. In the fourth quarter, Praj Industries Limited (Praj), a global leader in process engineering and equipment manufacturing for the ethanol and brewing industries, conducted extensive due diligence at the Luverne plant, and has confirmed these cost projections. Praj has subsequently signed a memorandum of understanding (MOU) wherein Praj will undertake to license up to 250 million gallons of isobutanol capacity for sugar-based ethanol plants over the next ten years.
With this data in hand, Gevo’s focus has turned to the licensing of its isobutanol technology. In addition to the Praj MOU, Gevo signed a letter of intent (LOI) in the fourth quarter to license its technology to Highland EnviroFuels’ sugar cane and sweet sorghum project based in Florida. These supplement the LOIs that were formerly reached with IGPC Ethanol Inc.based in Canada, and Porta Hnos S.A. based in Argentina. As a result of this interest, Gevo is targeting signing a binding contract with at least one licensee for its isobutanol technology in 2015.
Gevo, Inc., a renewable chemicals and biofuels corporation, focuses primarily on the production and sale of isobutanol and related products from renewable feedstocks. Isobutanol is a four-carbon alcohol, which is used as a specialty chemical in the production of solvents, paints, and coatings or as a value-added gasoline blendstock.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
